跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 500 条关于
“Jiangsu Hansoh”
全部
500
临床试验
71
药物
180
机构
83
资讯
166
去年
Hansoh Pharma's HS-20093 ADC Granted Breakthrough Therapy Designation for SCLC in China
5个月前
Tortugas Neuroscience Emerges from Stealth with $106M to Advance CNS Drug Pipeline Licensed from Eisai and Hansoh
9个月前
Glenmark Secures Global Rights to Third-Generation EGFR-TKI Aumolertinib for Lung Cancer Treatment
去年
Non-Small Cell Lung Cancer Clinical Trial Pipeline Sees Significant Growth
去年
KRAS Inhibitors Market Set to Exceed $2 Billion by 2030 with Next-Generation Therapies Advancing
去年
Schizophrenia Market Set for Strong Growth, Driven by Novel Therapies
去年
Chronic Spontaneous Urticaria Market Expected to Reach $36 Billion by 2035 as Novel Targeted Therapies Transform Treatment Landscape
去年
Hansoh Pharma's HS-20093 Granted Breakthrough Therapy Designation for Lung Cancer
去年
Recbio Initiates Phase III Trial of REC610 Shingles Vaccine in China
去年
Hansoh Pharma's HS-20093 Receives Breakthrough Therapy Designation in China for Small Cell Lung Cancer
第 1 页,共 17 页
上一页
下一页